Compare InMode Ltd (INMD) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
InMode Ltd vs Tempus AI — how do they compare? InMode Ltd trades at $14.07 (market cap $806.05M), while Tempus AI trades at $70.55 (market cap $12.77B). The key difference: Tempus AI is far larger — about 15.8× InMode Ltd's market cap, and Tempus AI is trading nearer its 52-week high, InMode Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold InMode Ltd for 29 Days and Tempus AI for 22 Days on average.
| INMD | TEM | |
|---|---|---|
Market Cap | $806.05M | $12.77B |
Volume | 511,446 | 8,980,490 |
Sector | Health | Broad Market / Factor |
52-Week High | $16.62 | $99.28 |
52-Week Low | $12.76 | $41.55 |
Typical Hold Time | 29 Days | 22 Days |
Enterprise Value | $309.39M | $13.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INMD trades at $14.01, showing minimal daily movement with a 0.14% gain. The stock faces bearish technical signals despite attractive valuation metrics including a P/E of 11.58 and EV/EBITDA of 4.43. Recent earnings show mixed results with Q2 2026 beating expectations but Q1 2026 missing, while the company faces shareholder activism from Steel Partners' $16.75 per share acquisition offer. Revenue guidance for 2026 remains stable at $365M-$375M.
The investment case balances strong profitability margins against technical weakness and activist pressure. With 45% analyst buy ratings and no sell recommendations, fundamental value appears intact, but near-term price action suggests caution. Key catalysts include Q3 2026 earnings and resolution of the acquisition proposal, while risks include execution challenges and macroeconomic headwinds affecting aesthetic medicine demand.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
